The 6th Annual NHLBI Progenitor Cell Translational Consortium (PCTC) 2023 is dedicated to developments in the study of progenitor cells biology towards application to lung, heart and blood diseases with a focus on the use of progenitor cell-based disease models to understand disease mechanisms and to develop therapies.
Topics
- The use of progenitor cells (including gene modified progenitors) and their differentiated progeny for cell therapy and tissue engineering
- Continued development of patient-specific disease models using progenitor cells and genome editing
- Expansion of efforts to employ direct reprogramming of cells in vivo to treat disease
- The development of strategies to promote the reparative potentials of endogenous progenitor cells
Who should Attend
Researchers, practitioners and physicians.
